TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11931781
Drug: Regimen A
Normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A (3 weekly injections as induction, followed by injections every 2 weeks)
Study: 11931781
Drug: Regimen B
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B (two injections at day 1 and day 15 as induction, followed by injections every 4 weeks)
Study: 10868864
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg)
Study: 7126418
Drug: Hydrochlorothiazide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (100 mg/day) alone
Study: 7126418
Drug: Hydrochlorothiazide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (100 mg/day) with spironolactone (100 mg/day)
Study: 7126418
Drug: Combination therapies
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapies (Hydrochlorothiazide and spironolactone)
Study: 7126418
Drug: Hydrochlorothiazide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (100 mg/day) once daily
Study: 25043278
Drug: Low-dose sIPV
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose sIPV
Study: 31151464
Drug: Oral taurine
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral taurine supplementation
Study: 28012528
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone 0.5 mg/kg (maximum dose 16 mg)
Study: 28012528
Drug: Pre‐incision infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre‐incision infiltration of local anesthesia (2-4 ml mixture with saline)
Study: 28012528
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone 0.5 mg/kg
Study: 25612858
Drug: Ceftriaxone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (2 g every 24 hours for 4 days)
Study: 19665347
Drug: MI-CBT (Motivational
Approvals — FDA: no, EMA: no, PMDA: no
Description: MI-CBT (Motivational Interviewing + Cognitive Behavioral Therapy)
Study: 14969576
Drug: Budesonide/formoterol 320/9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol 320/9 microg twice daily
Study: 11467142
Drug: 2-site regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-site regimen (0.2 ml at 2 sites on days 0, 3, 7; 1 site on days 28, 90)
Study: 11467142
Drug: 8-site regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-site regimen (0.1 ml at 8 sites on day 0; 4 sites on day 7; 1 site on days 28, 90)
Study: 9747644
Drug: Plantago Psyllium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plantago Psyllium (5 g t.i.d.)
Study: 20547600
Drug: Sodium salicylate
Normalized name: Sodium Salicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium salicylate injections into tender, thickened areas of subcutaneous tissue on the forearm and upper scapular region.
Study: 20547600
Drug: Sham injections
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injections consisting of pressure without skin penetration.
Study: 18400140
Drug: Dexmedetomidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.5 microg kg(‐1) administered intravenously over 60 s
Study: 18400140
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of 0.9% NaCl administered intravenously over 60 s (Control Group)
Study: 15746991
Drug: Prednisone 5
Normalized name: prednisone 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 5 mg/day
Study: 11955844
Drug: Double the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double the ACE inhibitor dose (n = 10)
Study: 11955844
Drug: Add an
Normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Add an angiotensin II antagonist (n = 10)
Study: 11955844
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (n = 10)
Study: 10206072
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with Mitoxantrone, methotrexate (+/‐ mitomycin C), and tamoxifen for four 3‐weekly cycles
Study: 10206072
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with Mitoxantrone, methotrexate (+/‐ mitomycin C), and tamoxifen
Study: 10206072
Drug: Non-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-treatment control group (20 patients)
Study: 2079058
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate 0.5 g.kg‐1 body mass
Study: 7418568
Drug: Daily regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily regimen of isoniazid (INH) plus rifampicin (RMP) plus ethambutol (EMB)
Study: 7418568
Drug: Twice-weekly regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly regimen of isoniazid (INH) plus rifampicin (RMP) plus ethambutol (EMB)
Study: 7418568
Drug: Daily regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily regimen of isoniazid (INH)
Study: 7418568
Drug: Twice-weekly regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly regimen of rifampicin (RMP)
Study: 28369299
Drug: Pentasa® enemas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentasa® enemas 25 mg/kg (up to 1g) daily for 3 weeks
Study: 22882430
Drug: Oral desensitization
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral desensitization with raw hen's egg starting from 0.27 mg (1 drop diluted 1:100) and increasing doses over 6 months
Study: 20727238
Drug: Gold kiwifruit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gold kiwifruit with iron-fortified breakfast cereal (16 mg Fe as ferrous sulfate) and milk
Study: 20727238
Drug: Banana with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Banana with iron-fortified breakfast cereal (16 mg Fe as ferrous sulfate) and milk
Study: 11447381
Drug: Rofecoxib (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib (12.5 mg, 25 mg)
Study: 9738560
Drug: Control (antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (antibiotics only)
Study: 30223903
Drug: Blended GP
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blended GP educational programme (online and face-to-face training) with proactive discussion of pain management and prescription of paracetamol and ibuprofen according to guidelines.
Study: 25771087
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) administered subcutaneously
Study: 25771087
Drug: Acenocoumarol (Vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acenocoumarol (Vitamin K antagonist)
Study: 23064902
Drug: Glutamine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine (15 g orally, three times daily)
Study: 18341663
Drug: Methyl aminolaevulinate-photodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyl aminolaevulinate-photodynamic therapy (MAL-PDT)
Study: 17065974
Drug: Antidepressant selection
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant selection based on drug factors (tolerability, interactions, cost), depression subtype, psychiatric and medical comorbidity, and stage of life.
Study: 17065974
Drug: Patient preference
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient preference for avoiding certain side effects and personal and family history of treatment response.
Study: 11121910
Drug: 5-day regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-day regimen with rabeprazole 10 mg b.d., clarithromycin 400 mg b.d. and amoxicillin 750 mg b.d.
Study: 11121910
Drug: 7-day regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 7-day regimen with rabeprazole 10 mg b.d., clarithromycin 400 mg b.d. and amoxicillin 750 mg b.d.
Study: 1350367
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of sodium cromoglycate
Study: 3553247
Drug: Clobetasol‐17‐propionate ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobetasol‐17‐propionate ointment
Study: 3553247
Drug: Both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs (Betamethasone and Clobetasol)
Study: 24612495
Drug: Various interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Various interventions to improve adherence (e.g., calendar blister packs, patient education programs)
Study: 24612495
Drug: Simplification of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simplification of drug regimens (e.g., reducing the number of pills taken per day)
Study: 23724808
Drug: Adapalene 0.1%
Normalized name: ADAPALENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapalene 0.1% gel plus nadifloxacin 1% cream (combination therapy)
Study: 23724808
Drug: Adapalene 0.1%
Normalized name: ADAPALENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapalene 0.1% gel (monotherapy)
Study: 20010312
Drug: Enzyme-linked immunosorbent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme-linked immunosorbent assay cutoff of 0.2 microg/mL
Study: 18829518
Drug: Ibandronate 150
Normalized name: ibandronate 150 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate 150 mg orally every month
Study: 19382218
Drug: Fluticasone propionate/salmeterol
Normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate/salmeterol (100/50 mcg twice daily)
Study: 19382218
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (100 mcg twice daily)
Study: 15688622
Drug: Pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin (PLD) 50 mg/m2 day 1 every 4 weeks
Study: 15688622
Drug: Topotecan 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan 1.5 mg/m2 daily for 5 days q 21
Study: 11301569
Drug: Ketoprofen 6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 6.25 mg
Study: 27027878
Drug: Insulin degludec/insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin degludec/insulin aspart (IDegAsp) once daily
Study: 21134466
Drug: Inactivated Ph.d.p.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated Ph.d.p. whole bacterial vaccine
Study: 19552838
Drug: Serum Chemerin
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum Chemerin levels in females (109 +/- 28 microg/L)
Study: 19552838
Drug: Serum Chemerin
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum Chemerin levels in OW/OB group (113 +/- 27 microg/L)
Study: 17094871
Drug: Oral melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral melatonin 3 mg (M3 group)
Study: 17094871
Drug: Oral melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral melatonin 5 mg (M5 group)
Study: 14743850
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (both groups)
Study: 9476036
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg zolmitriptan alone
Study: 9476036
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg zolmitriptan + 1 g paracetamol
Study: 9476036
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg zolmitriptan + 10 mg metoclopramide
Study: 9476036
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg zolmitriptan + 1 g paracetamol + 10 mg metoclopramide
Study: 3129954
Drug: Pethidine 30
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pethidine 30 mg and doxapram 45 mg
Study: 3129954
Drug: Pethidine 30
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pethidine 30 mg alone
Study: 20850831
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment group (electrical stimulation)
Study: 11952661
Drug: Topical mupirocin
Normalized name: mupirocin Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical mupirocin cream applied three times daily
Study: 11952661
Drug: Oral cephalexin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cephalexin, 250 mg four times daily
Study: 10217339
Drug: Caffeine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (100 mg four times daily)
Study: 10217339
Drug: Mexiletine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexiletine (200 mg oral dose)
Study: 7899419
Drug: piperacillin (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: piperacillin (12 g/d)/tazobactam (1.5 g/d)+amikacin
Study: 7899419
Drug: ceftazidime (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ceftazidime (3 g/d)+amikacin
Study: 822265
Drug: niflumic acid
Normalized name: niflumic acid
DrugBank: Niflumic acid (DB04552)
Approvals — FDA: no, EMA: no, PMDA: no
Description: niflumic acid (1000 mg per day)
Study: 822265
Drug: indometazin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: indometazin (100 mg per day)
Study: 24426779
Drug: menatetrenone 45
Normalized name: Menatetrenone 45 MCG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: menatetrenone 45 mg/day
Study: 24426779
Drug: alfacalcidol 0.5
Normalized name: alfacalcidol 0.5 MCG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: alfacalcidol 0.5 μg/day
Study: 15857725
Drug: Weekly individual
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly individual standardized interpersonal cognitive psychotherapy
Study: 15857725
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg buprenorphine every other day
Study: 14694974
Drug: Porcine-derived lung
Normalized name: porcine lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Porcine-derived lung surfactant therapy within the first hour of life (Group A, 35 neonates)
Study: 14694974
Drug: No surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No surfactant therapy within the first hour of life (Group B, 40 neonates)
Study: 14694974
Drug: Porcine-derived lung
Normalized name: porcine lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Porcine-derived lung surfactant therapy within the first hour of life (Group A)
Study: 14694974
Drug: No surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No surfactant therapy within the first hour of life (Group B)
Study: 2938515
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide as inhalation powder (40 micrograms)
Study: 31662373
Drug: Internet-Based Exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-Based Exercise programme (iBEAT-OA), 20-30 min daily for six weeks
Study: 30353809
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg regular‐release melatonin
Study: 22067793
Drug: LNG/EE (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNG/EE (90 mcg levonorgestrel/20 mcg ethinyl estradiol)
Study: 18798585
Drug: Topical 0.02%
Normalized name: tretinoin topical 0.02% topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.02% mitomycin-C drops twice a day for 2 weeks after pterygium excision
Study: 15851601
Drug: Clopidogrel and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel and Aspirin (dual therapy)
Study: 15851601
Drug: Aspirin monotherapy
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin monotherapy (control)
Study: 11403068
Drug: Heparin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (250 IU/h, adjusted in 125 IU/h steps, targeted ACT 180-210 s)
Study: 9663728
Drug: effervescent cimetidine
Normalized name: cimetidine Effervescent Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: effervescent cimetidine 200 mg
Study: 7833101
Drug: Fadrozole hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Fadrozole (DB16832)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fadrozole hydrochloride 0.5 mg bd
Study: 7833101
Drug: Fadrozole hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Fadrozole (DB16832)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fadrozole hydrochloride 1.0 mg bd
Study: 7833101
Drug: Fadrozole hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Fadrozole (DB16832)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fadrozole hydrochloride 2.0 mg bd
Study: 3275684
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg cabergoline
Study: 3275684
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg cabergoline
Study: 3275684
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg cabergoline (twice weekly)
Study: 1489388
Drug: Iodine-131 therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodine-131 therapy
Study: 31291863
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (group 2)
Study: 1489388
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (group 2)
Study: 860807
Drug: Oral diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diazepam and metoclopramide with a drink
Study: 26375928
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (30 IU)
Study: 23147384
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg day(‐1) GSK1521498
Study: 23147384
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg day(‐1) GSK1521498
Study: 3336100
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine viscous solution
Study: 29282731
Drug: TAU plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAU plus up to 16 sessions of individual formulation‐based CBT for ADHD
Study: 23615694
Drug: Aripiprazole once-monthly
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole once-monthly (ARI-OM)
Study: 19491792
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment during hospitalization
Study: 19491792
Drug: Conservative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative therapy following stapedoplasty (1 year or more earlier)
Study: 19491792
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with betahistine dihydrochloride (betaserk) during 2 months and 10-12 sessions of game exercises at a stabilographic complex
Study: 17110823
Drug: Nontricyclic antidepressant
Normalized name: TRICYCLIC ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nontricyclic antidepressant
Study: 9934406
Drug: Cetirizine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (10 mg/die per os) + Placebo of fluticasone (2 puff per nostril once daily by aerosol) for 60 days
Study: 9934406
Drug: Fluticasone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone (100 mg per nostril once daily by aerosol) + Placebo of cetirizine (per os) for 60 days
Study: 9934406
Drug: Cetirizine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (10 mg/die per os) + Fluticasone (100 mg per nostril once daily by aerosol) for 20 days
Study: 9934406
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Cetirizine and Fluticasone)
Study: 8148218
Drug: Colestipol 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestipol 10 g daily (administered as 5 g twice daily or 10 g once daily)
Study: 3246466
Drug: Carbohydrate (CHO)
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate (CHO) solution
Study: 3246466
Drug: Placebo (PL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL) solution
Study: 31305338
Drug: Methadone 5
Normalized name: methadone 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone 5 mg
Study: 31305338
Drug: Buprenorphine 0.4
Normalized name: buprenorphine 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 0.4 mg
Study: 16738349
Drug: Cognitive Stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Stimulation Therapy (CST) group intervention, twice weekly for 8 weeks
Study: 9102064
Drug: Etidronate 400
Normalized name: etidronate 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etidronate 400 mg once daily for 14 days followed by 76 days of 500 mg of elementary calcium once daily, repeated every 3 months.
Study: 9102064
Drug: Calcium 500
Normalized name: Calcium 500+D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium 500 mg once daily.
Study: 3896368
Drug: Short peri-operative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short peri-operative antibiotic course
Study: 3896368
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antibiotic course)
Study: 31819863
Drug: Silicone gel
Normalized name: SILTREX Silicone Gel-Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone gel treatment applied twice per day for two months on the surgical wound site.
Study: 31819863
Drug: Placebo (Vaseline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Vaseline) treatment applied twice per day for two months on the surgical wound site.
Study: 15889513
Drug: Medication (Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (Control group I)